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Background. Arteriosclerosis is a common cause of chronic morbidity and mortality. Myocardial infarction, stroke or other
cardiovascular events identify vulnerable patients who suffer from symptomatic arteriosclerosis. Biomarkers to identify
vulnerable patients before cardiovascular events occur are warranted to improve care for affected individuals. We tested how
accurately basic clinical data can describe and assess the activity of arteriosclerosis in the individual patient. Methodology/
Principal Findings. 269 in-patients who were treated for various conditions at the department of general medicine of an
academic tertiary care center were included in a cross-sectional study. Personal history and clinical examination were obtained.
When paraclinical tests were performed, the results were added to the dataset. The numerical variables in the clinical
examination were statistically compared between patients with proven symptomatic arteriosclerosis (n=100) and patients
who had never experienced cardiovascular events in the past (n=110). 25 variables were different between these two patient
groups and contributed to the disease activity score. The percentile distribution of these variables defined the empiric clinical
profile. Anthropometric data, signs of arterial, cardiac and renal disease, systemic inflammation and health economics formed
the major categories of the empiric clinical profile that described an individual patient’s disease activity. The area under the
curve of the receiver operating curve for symptomatic arteriosclerosis was 0.891 (95% CI 0.799-0.983) for the novel disease
activity score compared to 0.684 (95% CI 0.600-0.769) for the 10-year risk calculated according to the Framingham score. In
patients suffering from symptomatic arteriosclerosis, the disease activity score deteriorated more rapidly after two years of
follow-up (from 1.25 to 1.48, P=0.005) compared to age- and sex-matched individuals free of cardiovascular events (from 1.09
to 1.19, P=0.125). Conclusions/Significance. Empiric clinical profiling and the disease activity score that are based on
accessible, available and affordable clinical data are valid markers for symptomatic arteriosclerosis.
Citation: Mutschelknauss M, Kummer M, Muser J, Feinstein SB, Meyer PM, et al (2007) Individual Assessment of Arteriosclerosis by Empiric Clinical
Profiling. PLoS ONE 2(11): e1215. doi:10.1371/journal.pone.0001215
INTRODUCTION
Arteriosclerosis is a common, chronic and progressive disorder of
the large elastic and muscular arteries. It is complicated by
cardiovascular events such as myocardial infarction, stroke or
peripheral arterial occlusive disease [1]. Nearly 10% of patients in
the primary care setting suffer from symptomatic arteriosclerosis,
i.e. arteriosclerosis complicated by cardiovascular events [2]. It is
the leading cause of death in developed countries and its
prevalence is supposed to rise globally due to the worldwide
increase of diabetes and obesity [3–5]. The annual event rate for
patients with symptomatic arteriosclerosis is 4% [6]. Current
preventive management of this chronic disease is based on risk
assessment [7,8] and treatment of risk factors such as arterial
hypertension, smoking, diabetes or hypercholesterolemia. Howev-
er, conditions that affect risk, particularly cardiovascular risk, are
variable with time and geographic environment [9]. Therefore,
contemporary and regional patient cohorts are needed for the
timely adjustment of reference values. Furthermore, a test to
determine the vulnerability to develop arteriosclerosis [10,11] and
eventually cardiovascular events would clearly improve the
accuracy of risk prediction in the individual patient. The quest
for biomarkers that are suitable to diagnose arteriosclerosis in its
subclinical, asymptomatic stage is ongoing [12,13]. But neither
laboratory tests nor modern imaging modalities have substantially
forwarded the field so far [14–19]. In addition, non-invasive
coronary CT angiography and other diagnostic imaging modal-
ities are currently criticized for extraordinary high radiation
exposure leading to a significant increase in cancer [20,21]. In
order to address some of these issues, we used comprehensive
clinical bedside examination and applied the rules of differential
display for data analysis to determine the phenotype of patients
with symptomatic arteriosclerosis or vulnerable patients in our
hospital. We wished to test whether clinical findings, i.e. history
taking, physical examination and a few additional, common and
affordable bedside procedures would accurately describe the
activity of arteriosclerosis in the individual patient. We found that
this approach is at least as efficient as conventional risk assessment
and novel biomarkers [22] for the detection of vulnerable patients.
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Objectives
We tested to what extent basic, available and affordable clinical
data obtained from the patient’s history, physical examination and
paraclinical tests can be used to assess accurately the phenotype
and disease activity of patients with symptomatic arteriosclerosis.
Participating Patients
Between September 2003 and March 2005, all 718 in-patients
who were treated for any reason at a ward of the department of
medicine were screened for exclusion criteria to participate in this
study. Exclusion criteria were either inability to give informed
consent or terminal illness. 431 patients without exclusion criteria
were asked to participate. 162/431 (38%) patients refused and
269/431 (62%) patients gave written informed consent. These
patients were grouped in three categories based on the clinical
history: group 1–no cardiovascular events in the past; group 2–
cardiovascular events in the past which define symptomatic
arteriosclerosis; group 3–symptoms compatible with symptomatic
arteriosclerosis, but clinical evidence to prove it was lacking. For
the data-based clinical disease profile, patients without cardiovas-
cular events (group 1) and patients with proven, symptomatic
arteriosclerosis (group 2) were compared (Table 1). Cardiovascular
events which defined symptomatic arteriosclerosis in this patient
cohort were a) for coronary heart disease: myocardial infarction, angina
pectoris with signs of myocardial ischemia, history of coronary
bypass surgery or other revascularization procedures, b) for
cerebrovascular disease: ischemic stroke, history of carotid surgery, c)
for peripheral arterial occlusive disease: ankle brachial index,0.9 [23]
and symptoms of claudicatio intermittens, significant stenosis of
arteries and symptoms of claudicatio, history of peripheral bypass
surgery or other revascularization procedure, d) for aortic
arteriosclerosis: symptomatic aortic aneurysm, diameter of infrarenal
aorta .3 cm [24], aortic surgery for arteriosclerosis and e) for
arteriosclerosis of the kidney: renal artery stenosis, impaired renal
function [25] with normal urine analysis, history of renal artery
revascularization procedures. Male sex, arterial hypertension,
diabetes mellitus, dyslipidemia, smoking and a positive family
history for cardiovascular disease were six conventional cardio-
vascular risk factors which were assessed based on the clinical
history [26].
Ethics
The study protocol was approved by the independent ethical
review board. Patients who fulfilled the inclusion criteria and were
willing to participate gave written informed consent.
Comprehensive clinical assessment
All participants were subject to a standardized interview (H,
history) and examined in a standardized clinical examination (C).
Body weight and size, waist and hip circumference, blood pressure
and heart rate were measured on both arms in the standing
position first. Thereafter, the examination was continued in the
supine position. Blood pressure and heart rate measured in supine
position were usually obtained at the end of the examination,
together with the determination of the ankle brachial index (ABI)
that was assessed using bedside doppler ultrasound (Dopplex
5 MHz, HNE Healthcare GmbH, Hilden, Germany) [23].
Patients with incompressible leg arteries had an ABI of more
than 1.5. These excessively high indexes that were found in 13
patients were excluded from the dataset. The patient’s record
served as a source for additional information such as laboratory
tests (L), X-rays (X), electrocardiogram (E), stress test or
echocardiogram. No additional laboratory tests were performed
except for those requested by the treating physicians. The full
clinical assessment was entered into an electronic data base and
included 75 numeric variables (see Table S1) that were selected for
further analysis. 14 (19%) were obtained from the interview, 19
(25%) from the clinical examination, 33 (44%) from the laboratory
tests and 9 (12%) from x-ray, electrocardiogram, stress test or
echocardiogram. For 15 of these 75 parameters, the dataset was
incomplete, i.e. information from less than 75% of the patients was
available (Table S1).
Empiric clinical disease profiling and disease activity
score
The 60 nearly complete variables were compared between patients
without cardiovascular events in the past (group 1) and patients
with proven symptomatic arteriosclerosis (group 2) using the Mann
Whitney U test (Table S1). For 25 variables (42%), the P-value was
below 0.1 and these parameters were selected to be part of the
data-based, empiric clinical disease profile (Table 2). For both
groups, the percentile distribution of the data was calculated and
the quartile ranges are shown (Table 2). The group of patients with
the disease, i.e. with proven symptomatic arteriosclerosis (group 2,
n=100 patients) defined the empiric clinical disease profile. The
quartile range served for color coding the patient’s individual data
(Table 2 and Figure 1A). For most of the numerical variables,
patients with symptomatic arteriosclerosis had higher median
values than the patients without cardiovascular events. Therefore,
the lowest quartile was assigned light green, the 2
nd quartile
yellow, the 3
rd quartile orange and the 4
th quartile red. Values
below the minimal value of the data-set were coded as dark green
and values above the maximal value were coded as dark red.
Exceptions to this rule were the ankle brachial indexes, the
peripheral heart rate at standing position, the creatinine clearance
and the hemoglobin concentration. For these 5 variables, the
patients with symptomatic arteriosclerosis had lower median
values compared to the asymptomatic patients, and therefore
colorcoding followed the opposite rule: the highest quartile range
was assigned light green, the 3rd yellow, the 2
nd orange and the
lowest quartile range red (Figure 1A). This mathematical trans-
formation allows standardized representation of clinical data in
various formats. For example, an individual patient’s empiric
clinical profile can be intuitively determined when his personal
data are placed onto the color-coded reference range (Figure 1B).
Alternatively, a disease activity score can be calculated as follows:
for the light and dark green color, a variable score point of 0, for
the yellow color a score point of 1, for the orange color a point of 2
and for the red and dark red color a point of 3 can be given
(Figure 1B). The individual disease activity score can then be
calculated as the average variable score point. The variable score
points can also be transferred into machine-readable bar-codes
(Figure 1C) that are useful for any digital processing and large-
scale management of clinical data such as during epidemiologic
studies, e-health applications or comparative assessment of health
care quality. Finally, a more precise and quantitative clinical
profile can be derived using percentile distributions with infinite
resolution as shown in Figure 1D.
Statistical analysis
All statistical analyses were performed using SPSS version 12.0
(SPSS Inc., Chicago IL, USA). The numeric data obtained in the
group of patients with symptomatic arteriosclerosis were compared
to the patients without cardiovascular events using the Mann-
Phenotyping Complex Diseases
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factors was compared between the two groups using the x
2- test.
Receiver operating curves (ROC) were used to assess the accuracy
of the disease activity score as a diagnostic test. The disease activity
score of a subgroup of 34 age- and sex-matched patients that were
examined on two occasions at an interval of two years was
compared using the Wilcoxon test. P-values,0.05 were supposed
to indicate a significant difference between the groups. Unless
indicated otherwise, median values are shown and interquartile
range is given in brackets.
RESULTS
Characteristics of the patient cohort
Of the 269 patients who participated in this study, 100 (37%) had
symptomatic arteriosclerosis, i.e. they had suffered from cardio-
Table 1. Patient characteristics
..................................................................................................................................................
No cardiovascular events
(n=110)
Symptomatic
arteriosclerosis (n=100) P-values
#
Cardiovascular risk factors n (%)
Male sex 51 (46.4) 57 (57) 0.095
Age (years) 56.00 72.00 ,0.001
Body mass index (kg/m
2) 25.6 26.40 0.085
Arterial hypertension 40 (36.4) 67 (67) ,0.001
Diabetes mellitus 12 (10.9) 30 (30) 0.005
Dyslipidemia 9 (8.2) 50 (50) ,0.001
Smoking 57 (51.8) 61 (61) 0.017
Family history of cardiovascular disease 48 (43.6) 61 (61) 0.038
Drugs at examination n (%)
Antiplatetelet drugs 7 (6.4) 69 (69) ,0.001
Anticoagulants 27 (24.6) 36 (36) 0.07
Nitrates 1 (0.9) 18 (18) ,0.001
Betablockers 19 (17.3) 60 (60) ,0.001
Diuretics 17 (15.5) 48 (48) ,0.001
ACE inhibitors 14 (12.7) 56 (56) ,0.001
Angiotensin II receptor blockers 8 (7.3) 11 (11) 0.347
Ca
2+ channel blockers 7 (6.4) 26 (26) ,0.001
Oral glucose-lowering agents 9 (8.2) 14 (14) 0.178
Insulin 5 (4.6) 21 (21) ,0.001
Statins 14 (12.7) 68 (68) ,0.001
Other drugs 5 (4.6) 8 (8) 0.299
Cardiovascular events defining symptomatic arteriosclerosis %
Coronary heart disease - 60
Myocardial infarction - 49
Significant stenosis of coronary arteries (angiographic findings) - 23
Angina pectoris with signs of myocardial ischemia (e.g. exercise testing) - 9
History of revascularization - 14
Cerebrovascular disease - 26
Ischemic stroke - 26
Peripheral arterial occlusive disease - 27
Ankle-brachial-index,0.9 and symptoms of claudicatio intermittens - 14
Angiographically proven and symptoms of claudicatio intermittens - 5
History of revascularization - 17
Arteriosclerosis of the aorta - 7
Arteriosclerosis of the kidney - 11
Number of organs affected by cardiovascular events
1 -7 2
2 -2 6
$3 -2
#The two patient groups were compared using the Mann-Whitney-U-Test (for numerical data) or the x
2-test (for non-numerical data)
doi:10.1371/journal.pone.0001215.t001
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PLoS ONE | www.plosone.org 4 November 2007 | Issue 11 | e1215vascular events in the past. For 40 patients, the first
cardiovascular event was the reason for the current admission
to the hospital. For the other 60 patients, the first cardiovascular
event did occur on average 5 [3–12] years ago. 110 (41%) had
no history of cardiovascular events such as myocardial in-
farction, stroke, intermittent claudication, revascularization
procedures or other disease defining conditions (Table 1). For
59 (22%) patients, the definite allocation to either one of these
two groups was not possible. The characteristics of the patients
without cardiovascular events in the past and of the patients with
proven symptomatic arteriosclerosis are summarized in Table 1.
On average, patients with symptomatic arteriosclerosis were
older, and most conventional risk factors were significantly more
common in this group. Smoking and a positive family history of
cardiovascular events were the most prevalent risk factors in
both patient groups (Table 1). Among vulnerable patients with
symptomatic arteriosclerosis, 60% had coronary heart disease,
26% had cerebrovascular disease, 27% peripheral arterial
occlusive disease, 7% aortic and 11% renal arteriosclerosis.
For 27 patients, more than one vascular bed was affected by the
disease. These rates of organ involvement by arteriosclerosis
were similar to findings obtained in other population-based
Figure 1. Empiric clinical profiles of arteriosclerosis and disease activity score. A. Reference range of data obtained from each of the 25
significantly different variables in symptomatic patients. An individual patient’s data (represented as white dots) are superposed onto the color-coded
quartile distribution. B. The same individual patient’s color-coded empiric clinical disease profile of arteriosclerosis. The color-coded profile can be
transformed into numbers: green=0, yellow=1, orange=2 and red=3. The arithmetic mean of these numbers is equivalent to the disease activity
score. C. The color- or number-coded profiles can be transformed into a barcode. D. The individual patient’s quantitative percentile profile.
doi:10.1371/journal.pone.0001215.g001
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PLoS ONE | www.plosone.org 5 November 2007 | Issue 11 | e1215surveys [2,6] and provide evidence for an unbiased patient
selection.
The majority of the 25 variables that were found to be different
between vulnerable patients and patients free of cardiovascular
events was obtained in the bedside examination: 6 (24%) from the
interview and 11 (44%) from the clinical exam. Only 5 (20%) were
results from laboratory tests and 3 (12%) from chest X-ray or
electrocardiogram (Table 2).
Phentoypical description of vulnerable patients with
arteriosclerosis using empiric clinical profiling
Most of the 25 variables which were significantly different in this
systematic and comprehensive comparison of clinical data from
symptomatic and asymptomatic patients reflect important and
well-known clinical signs of arteriosclerosis or associated condi-
tions: the anthropometric data reveal abdominal obesity [27,28],
the elevated systolic blood pressure [29] is caused by reduced wall
compliance and the reduced ankle brachial index [23,30] is
a consequence of obstructed arteries. Cardiomegaly is a sign of left
ventricular hypertrophy [31], QT prolongation may correlate with
electric vulnerability [10,11], diminished creatinin clearance and
glucosuria indicate kidney injury [32,33]. Anemia, monocytosis
and elevated blood sedimentation rate are signs of chronic
inflammation [34] and finally, the high number of drugs and
repetitive hospitalizations are health economic aspects of symp-
tomatic arteriosclerosis (Figure 1A). These categories, which
emerged directly from the data analysis can be further used to
manage arteriosclerosis both in individual patients and patient
groups.
For example, the male patient whose data are shown in
Figure 1A (white circles) and Figure 1B had a myocardial
infarction three years ago. His disease profile draws the physician’s
attention to abdominal obesity as the major remaining, intuitively
apparent sign of the disease under combined anti-hypertensive and
lipid lowering treatment.
Since the rules of differential display were applied to analyze the
clinical data, an alternative approach of empiric disease modeling
was explored in this patient cohort. The color-coded profiles
obtained from vulnerable patients were aligned in an array format
(Figure 2). The cohort was split according to gender into female
and male patients. This clinical array representation revealed two
obvious, gender-specific differences in the phenotype of symptom-
atic arteriosclerosis. Female patients had higher, partially un-
controlled systolic blood pressure (145 (125–160) mmHg versus
130 (115–148) mmHg, P=0.02, see Figure 2, black arrow) despite
of taking the same number of antihypertensive drugs (on average 2
(1–2) drugs). In contrast, male patients were more obese having
a significantly higher body mass index (27.7 (24.6–30.7) kg/m
2
versus 25.4 (23.3–28.1) kg/m
2, P=0.04 and a higher waist hip
ratio (1.02 (1.0–1.07) versus 0.91 (0.88–0.97), P,0.001) than
female patients (Figure 2, white arrow). These gender-specific
differences in anthropometric data and systolic blood pressure that
were revealed by the empiric clinical profiling of arteriosclerosis in
vulnerable patients were less pronounced (waist-hip ratio) or did
follow the opposite direction (systolic blood pressure) in patients
free of cardiovascular events.
Diagnostic accuracy and prospective evolution of
the disease activity score
We evaluated the diagnostic accuracy of the disease activity score
to identify individuals with symptomatic arteriosclerosis (Figure 3).
The area under the curve (AUC) of the ROC was 0.891 (95% CI
0.799-0.983) and when a cut-off value of 1.05 was chosen, the
sensitivity was 81% and the specificity 70% to diagnose systemic
cardiovascular disease. For the number of risk factors, the AUC
was 0.836 (95% CI 0.705-0.966), and for the 10-year risk
according to the Framingham score, the AUC was 0.684 (95%
CI 0.600-0.769). To add the number of risk factors to the disease
Figure 2. The clinical disease array. The color-coded empiric clinical
disease profiles (see Figure 1B) of the 43 female and 57 male
symptomatic patients were aligned and sorted according to disease
activity score. Male and female patients were significantly different in
anthropometric (white arrow) and blood pressure data (black arrow).
doi:10.1371/journal.pone.0001215.g002
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the test although the two variables showed only moderate
correlation with each other (R=0.48). In this group of patients,
the disease activity score had the best diagnostic accuracy for
symptomatic arteriosclerosis.
The disease activity score increased with age. This age-
dependent increase was much more pronounced in patients with
symptomatic AS than in individuals free of cardiovascular events
(Table 3). Therefore we tested the hypothesis that in patients with
symptomatic arteriosclerosis the disease activity score deteriorated
more rapidly with time than in asymptomatic individuals
(Figure 4). 34 age and gender matched patients, 16 asymptomatic
and 18 symptomatic (median age: 72 years), were reexamined
after 2 years. During the two years of follow-up, one patient from
the symptomatic group was re-admitted for a cardiovascular event
(coronary angioplasty). In patients with symptomatic arterioscle-
rosis, the disease activity score deteriorated more rapidly (from
1.25 to 1.48, P=0.005) than in asymptomatic individuals (from
1.09 to 1.19, not significant).
DISCUSSION
We demonstrate that comprehensive clinical bedside examination
including the interview, physical exam and a few paraclinical tests,
can accurately describe the phenotype of patients with symptom-
atic arteriosclerosis. Comprehensive, quantitative phenotyping in
the field of cardiovascular diseases was first discovered and
developed by physiologists and formed the basis for sophisticated
phenotype-genotype correlations in an animal model of hyperten-
sion [35]. For the clinical disease phenotype described herein we
followed similar mathematical rules of data analysis. We found 25
numeric variables that contributed to the phenomenological
description of patients with the disease, i.e. symptomatic
arteriosclerosis characterized by cardiovascular events. The color
coded, bar coded or quantitative percentile profiles serve to
visualize the individual patient’s disease phenotype. The clinical
disease array that is formed by a cohort of vulnerable patients with
symptomatic arteriosclerosis enables data analysis with the
purpose to identify specific subgroups with associated conditions.
For example, we found that in this group of patients, women with
symptomatic arteriosclerosis had higher and partially uncontrolled
systolic blood pressure despite of taking the same number of
antihypertensive drugs as men. Finally, the calculated disease
activity score had a respectable diagnostic power to discriminate
between symptomatic and asymptomatic patients. It is at least as
efficient as the number of cardiovascular risk factors. In addition, it
deteriorated more rapidly over a short period of time in
symptomatic patients. A finding that further supports its value as
a biological activity marker of arteriosclerosis.
Based on the diagnostic accuracy of the disease activity score in
this cohort of patients we assume that it may also represent
a predictive test for patients admitted to this hospital. Both the
absolute value of the disease activity score at any given time and its
evolution with time could be important for the precise prediction
of cardiovascular events in an individual patient. If it would reflect
subclinical disease and identify patients susceptible for arterial
injury and cardiovascular events it would clearly improve
individualized long-term management of patients at risk. The
present study has been performed in in-patients. Despite of this
pre-selection bias the prevalence of cardiovascular events in the
study population is similar to the reported data in outpatient
cohorts [2,6]. In order to improve the disease activity score as
a predictive tool we will have to explore which variables change
early in the course of arteriosclerosis, particularly in its
asymptomatic stage. All these hypotheses and the deduced
mathematical models have to be tested in prospective clinical
trials and need to be confirmed in a population based cohort.
Finally, the individual empiric data-based disease profile could
be used to test the efficacy of preventive or therapeutic
interventions to treat arteriosclerosis. For example, any successful
intervention leading to weight loss and reduced abdominal obesity
may lead to quite obvious changes in a patient’s phenotype and
may even affect associated risk factors as shown by others [36].
The color coded disease profile may serve as a surrogate marker
for the intuitive visualization of early responses to therapy.
Figure 3. Diagnostic accuracy of the disease activity score. Sensitivity
and specificity of the disease activity score to distinguish between
asymptomatic and symptomatic patients is shown as receiver operating
curve. Area under the curve is 0.891. The AUC for the null hypothesis is
0.5.
doi:10.1371/journal.pone.0001215.g003
Table 3. Disease activity score in different age categories
..................................................................................................................................................
,40 years 40–59 years 60–79 years .80 years
Disease activity score
No cardiovascular events 0.8 (0.6–0.8) 0.8 (0.5–1.0) 1.0 (0.8–1.4) 1.0 (0.9–1.2)
n=17 n=49 n=38 n=5
Symptomatic arteriosclerosis 0.6 (0.5–0.6) 1.0 (0.7–1.4) 1.4 (1.2–1.7) 1.7 (1.4–1.8)
n = 2 n = 1 1n = 7 2n = 1 5
P-value 0.352 0.106 ,0.001 0.009
doi:10.1371/journal.pone.0001215.t003
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PLoS ONE | www.plosone.org 7 November 2007 | Issue 11 | e1215Conditions that prevent or precipitate the development of
symptomatic arteriosclerosis evolve with time and may also be
different in various regions of the world [4,9]. Therefore, this data-
based, empiric clinical disease profile may differ in ten or twenty
years from now and it may be different in medical centers in Asia,
America or Africa. For the same reason, the reference range that
defines this disease profile for symptomatic arteriosclerosis cannot be
simply adopted by another institution. It should first be established
on site. The quartile distribution of the different variables may
represent a common ground for standardized comparisons of the
disease phenotype and the activity score determined in different
institutions. The optimal set of data, the size of the patient cohort
and the time window for reference range calculations needs to be
determined in future studies. Novel biomarkers will be tested for
their capacity to improve the diagnostic accuracy of the clinical
disease activity score presented herein.
In conclusion, affordable, available and accessible clinical data
collected in a standardized manner and analyzed according to the
rules of differential display result in an accurate description of the
phenotype of patients with a complex disease, e.g. symptomatic
arteriosclerosis. Data-based empiric clinical profiling visualizes an
individual patient’s disease phenotype quantitatively and it may
form the basis of personalized risk assessments and interventions.
SUPPORTING INFORMATION
Table S1 Numerical variables obtained from the patients.
Complete dataset from which the empiric clinical profile was
obtained.
Found at: doi:10.1371/journal.pone.0001215.s001 (0.54 MB
DOC)
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